Moreover, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown anti-proteinuric/albuminuric and renoprotective effects beyond their glucose-lowering effects in DN patients, through the monotherapy or on the top of RAAS inhibition. Here, GCG is linked to liver dysplastic nodule.